Charles Reynolds

Ali Mirzazadeh, Simon Cadavid, Kaiwen Zha et al.

Antidepressant nonadherence is pervasive, driving relapse, hospitalization, suicide risk, and billions in avoidable costs. Clinicians need tools that detect adherence lapses promptly, yet current methods are either invasive (serum assays, neuroimaging) or proxy-based and inaccurate (pill counts, pharmacy refills). We present the first noninvasive biomarker that detects antidepressant intake from a single night of sleep. A transformer-based model analyzes sleep data from a consumer wearable or contactless wireless sensor to infer antidepressant intake, enabling remote, effortless, daily adherence assessment at home. Across six datasets comprising 62,000 nights from >20,000 participants (1,800 antidepressant users), the biomarker achieved AUROC = 0.84, generalized across drug classes, scaled with dose, and remained robust to concomitant psychotropics. Longitudinal monitoring captured real-world initiation, tapering, and lapses. This approach offers objective, scalable adherence surveillance with potential to improve depression care and outcomes.

Andrew M. Webb, Charles Reynolds, Wenlin Chen et al.

End-to-End training (E2E) is becoming more and more popular to train complex Deep Network architectures. An interesting question is whether this trend will continue-are there any clear failure cases for E2E training? We study this question in depth, for the specific case of E2E training an ensemble of networks. Our strategy is to blend the gradient smoothly in between two extremes: from independent training of the networks, up to to full E2E training. We find clear failure cases, where over-parameterized models cannot be trained E2E. A surprising result is that the optimum can sometimes lie in between the two, neither an ensemble or an E2E system. The work also uncovers links to Dropout, and raises questions around the nature of ensemble diversity and multi-branch networks.